Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001172661-25-002414
Filing Date
2025-05-16
Accepted
2025-05-16 16:42:01
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9417
  Complete submission text file 0001172661-25-002414.txt   11076
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Subject) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90187 | Film No.: 25959990
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 200 GREENWICH AVENUE 3RD FLOOR GREENWICH CT 06830
Business Address 200 GREENWICH AVENUE 3RD FLOOR GREENWICH CT 06830 2034090812
Deep Track Capital, LP (Filed by) CIK: 0001856083 (see all company filings)

EIN.: 853360885 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G